Enhancement of cisplatin sensitivity in lewis lung carcinoma by liposome-mediated delivery of a survivin mutant by Yu, Dan-Dan et al.




© 2010 Yu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attri-
bution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Research Enhancement of cisplatin sensitivity in lewis lung 
carcinoma by liposome-mediated delivery of a 
survivin mutant
Dan-Dan Yu†1,2, Chun-Ting Wang*†1, Hua-Shan Shi1, Zhi-Yong Li1, Li Pan1, Qing-Zhong Yuan1, Fei Leng1, Yuan Wen1, 
Xiang Chen1 and Yu-Quan Wei1
Abstract
Background: A high concentration of cisplatin (CDDP) induces apoptosis in many tumor cell lines. CDDP has been 
administered by infusion to avoid severe toxicity. Recently, it has been reported that changes in survivin expression or 
function may lead to tumor sensitization to chemical and physical agents. The aim of this study was to determine 
whether a dominant-negative mouse survivin mutant could enhance the anti-tumor activity of CDDP.
Methods: A plasmid encoding the phosphorylation-defective dominant-negative mouse survivin threonine 
34Talanine mutant (survivin T34A) complexed to a DOTAP-chol liposome (Lip-mS) was administered with or without 
CDDP in Lewis Lung Carcinoma (LLC) cells and in mice bearing LLC tumors, and the effects on apoptosis, tumor growth 
and angiogenesis were assessed. Data were analyzed using one-way analysis of variance(ANOVA), and a value of P < 
0.05 was considered to be statistically significant.
Results: LLC cells treated with a combination of Lip-mS and CDDP displayed increased apoptosis compared with those 
treated with Lip-mS or CDDP alone. In mice bearing LLC tumors and treated with intravenous injections of Lip-mS and/
or CDDP, combination treatment significantly reduced the mean tumor volume compared with either treatment alone. 
Moreover, the antitumor effect of Lip-mS combined with CDDP was greater than their anticipated additive effects.
Conclusion: These data suggest that the dominant-negative survivin mutant, survivin T34A, sensitized LLC cells to 
chemotherapy of CDDP. The synergistic antitumor activity of the combination treatment may in part result from an 
increase in the apoptosis of tumor cells, inhibition of tumor angiogenesis and induction of a tumor-protective immune 
response.
Background
There is a great deal of evidence that cisplatin (cis-diam-
mine dichloroplatinum (II); CDDP) induces apoptosis in
many tumor cell types. In the clinic, determining the
greatest anti-tumoral efficiency using the lowest possible
dose is a very difficult problem. Genetic therapy is con-
sidered to have enormous potential for resolving this
issue.
A novel member of the inhibitor of apoptosis protein
family (IAP), designated survivin [1], was recently identi-
fied by hybridization screening of human genomic librar-
ies with the complementary DNA (cDNA) of a factor Xa
receptor, effector cell protease receptor 1[2]. Unlike all
other IAPs, survivin is expressed during development
and by common human cancers, but is undetectable or
detected at extremely low levels in normal adult tis-
sues[1]. Survivin therefore has become an attractive tar-
get for novel anticancer interventional agents[3]. In
recent years, considerable effort has been expended
towards counteracting survivin, including development
of antisense oligonucleotides[4], hammerhead
ribozymes[5], RNA interference[6,7], cancer vaccines[8]
and dominant-negative mutants[9]. Several preclinical
studies have already demonstrated that down-regulation
of survivin expression or function could inhibit tumor
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growth, increase spontaneous and induced apoptosis and
sensitize tumor cells to anticancer agents.
Phosphorylation of survivin at Thr 34 by the cyclin-
dependent kinase cdc2 is believed to promote physical
interaction between survivin and caspase-9, resulting in
caspase-9 inhibition to reduce apoptosis[10]. It was
reported that the survivin mutant Thr34TAla (survivin
T34A) could abolish a phosphorylation site for cdc2-
cyclin B1 and prevent survivin binding to activated cas-
pase-9[11]. This reduced tumor cell proliferative poten-
tial and led to caspase-dependent apoptosis in melanoma
cell lines[9]. It also increased the apoptosis of tumor cells,
inhibited tumor angiogenesis and induced a tumor-pro-
tective immune response [11]. It was found that greater
efficiency was attained in suppression of murine breast
cancer by using a plasmid encoding the phosphorylation-
defective mouse survivin T34A mutant complexed to
DOTAP-chol liposomes (Lip-mS) [11]. As a result, the
present study was designed to determine whether Lip-mS
could enhance the antitumor activity of CDDP chemo-
therapy and to explore the possible mechanisms of inter-
action between survivin targeting-agents and
chemotherapy.
Methods
Cell lines and culture conditions
The Lewis Lung Carcinoma (LLC) cell line of C57BL/6
mouse origin was purchased from the American Type
Culture Collection (ATCC, Rockville, MD), cultured in
DMEM (Gibco BRL, Grand Island, N.Y.) supplemented
with 10% heat-inactivated fetal bovine serum (FBS), and
maintained in a humidified incubator at 37°C in a 5% CO2
atmosphere.
Plasmid DNA preparation
The recombinant plasmid encoding the phosphorylation-
defective mouse survivin threonine 34Talanine mutant
(pORF9-msurvivinT34A, mS) and pORF9-mcs (null plas-
mid) were each purchased from InvivoGen Corporation
(San Diego, CA, USA) and confirmed by restriction
endonuclease analysis, PCR and DNA sequence analysis.
The plasmid was prepared using the Endofree Plasmid
Giga kit (Qiagen, Chatsworth, CA). Endotoxin levels of
the prepared plasmid DNA were determined by Tachy-
pleus Amebocyte Lysate (TAL). No genomic DNA, small
DNA fragments, or RNA were detected in the plasmid
DNA and the OD260/280 ratios of the DNA were
between 1.8 and 2.0. The DNA was dissolved in sterile
endotoxin-free water and stored at -20°C until use.
Preparation of DOTAP-chol liposome/plasmid DNA
DOTAP was purchased from Avanti Polar Lipids (Alabas-
ter, AL) and highly purified cholesterol (Chol) was pur-
chased from Sigma (St. Louis, MO). DOTAP-chol
liposomes were prepared using the procedure described
previously[11]. DNA:liposome mixtures were also pre-
pared in accordance with a previously-described method
[12]. Briefly, DOTAP-chol (20 mM) and plasmid DNA
stock solution diluted in 5% dextrose in water (D5W)
were mixed in equal volumes to give a final concentration
of 4 mM DOTAP-chol, i.e., 150 μg DNA in 300 μL final
volume (ratio, 1:2.6). These reagents were diluted and
mixed at room temperature. The DNA solution was
added to DOTAP-chol liposomes and rapidly mixed by
pipetting up and down twice with the pipette tip. The
DNA:liposome mixture thus prepared was precipitate-
free and used for all the in vivo experiments. The size of
the DNA fragments in the DNA:liposome mixture was
determined to be in the range of 300-325 nm.
Flow cytometric analysis
LLC cells were seeded in a 6-well plate and incubated for
24 h, then treated with normal saline (NS), CDDP, Lip-
null, Lip-mS, or Lip-mS+CDDP (DNA at 1 μg/mL and
CDDP at 4 μg/mL). Forty-eight hours later, the cells were
washed with PBS and resuspended in propidium iodide/
RNase A solution (0.5 mL), incubated at 37°C for 30 min
and analyzed by flow cytometry.
Animal studies
Studies involving whole mice were approved by the Insti-
tute's Animal Care and Use Committee. Female C57BL/6
mice of 6 to 8 weeks old were purchased from the experi-
mental animal center of Sichuan University (Chengdu,
Sichuan Province, China) and challenged subcutaneously
(s.c.) with LLC cells (5 × 105 cells in 50 μL PBS) in the
right flank. Mice were randomly divided into 4 groups (8
mice per group) and treated with NS, Lip-mS, CDDP or
Lip-mS + CDDP until the tumors had mean diameter of 3
mm. Lip-mS was injected into mice via the tail vein at 5
μg per day once daily for 10 days (days 0 to 9) and CDDP
(made in the Qilu Shandong Medical Factory) was
injected into mice via the tail vein at 1 mg/kg per week
(days 1, 8). Tumor size was determined by caliper mea-
surement of the largest and perpendicular diameters
every two days. Tumor volume was calculated according
to the formula V = 0.52ab2 (a is the largest superficial
diameter and b is the smallest superficial diameter).
Protein extraction and Western blot analysis
Tumor tissue samples were ground into powder under
liquid nitrogen by milling in mortar, and lysed in RIPA
lysis buffer (50 mM Tris-HCl (pH 7.4), 0.25% sodium
deoxycholate, 150 mM NaCl, 1% nonidet P-40 (NP-40), 1
mM EDTA, 1 mM NaF, 1 mM Na3V4, 1 mM phenylm-
ethylsulfonyl fluoride). After being quantifided by Brad-
ford assay, lysates were subjected to 12% SDS-PAGE
(sodium dodecyl sulfate polyacrylamide gel) electropho-Yu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:46
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resis, electroblotted with Sartoblot onto a PVDF mem-
brane (Millipore, Bedford, MA) for 1 hr at 100 V, and
then membrane blots were blocked at 4°C in 5% non-fat
dry milk, washed, and probed with rabbit anti-mouse
Caspase 9 antibody (Abcam, Cambridge, United King-
dom) at 1:1000 and anti-actin antibody (Santa Cruz Bio-
technology, Santa Cruz, CA) at 1:100. The blots were
labeled with horseradish peroxidase-conjugated second-
ary antibody and visualized by chemiluminescence detec-
tion.
Terminal deoxynucleotidyl transferase-mediated dUTP nick 
end-labeling (TUNEL) assay
The mice were sacrificed by cervical dislocation on day
16 after the initiation of Lip-mS administration. Primary
tumors were excised, fixed in 10% neutral-buffered form-
alin solution and embedded in paraffin. Contiguous 3-5
μm sections were mounted. In order to highlight the cells
that were undergoing apoptosis, unstained sections
mounted in silanized slides were subjected to fluorescent
in situ TUNEL assay using an in situ apoptotic cell detec-
tion kit (Promega, Madison WI, USA), according to the
manufacturer's protocol. Representative images were
taken under a light microscope (×200) in randomly-
selected fields.
CD31 immunohistochemical evaluation
Immunohistochemistal analyses of microvessel forma-
tion were performed with goat anti-mouse CD31 anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA) using
the labeled streptavidin-biotin method. Briefly, sections
were deparaffinized in xylol and rehydrated in a graded
alcohol series. Antigen retrieval was carried out by auto-
claving sections in retrieval buffer (10 mM EDTA citrate
buffer, pH 6.0) for 3 min in saturated steam after up-pres-
sure gaining (126, 1.6 bars, 23 psi). Endogenous peroxi-
dase activity was blocked by incubation in 3% hydrogen
peroxide at room temperature in the dark for 20 min.
Non-specific binding of reagents was quenched by incu-
bation of sections for 20 min in 5% normal rabbit serum.
Sections were then incubated with goat anti-mouse CD31
(dilution 1/200) antibody overnight at 4°C, followed by
incubation with biotinylated rabbit antigoat IgG, and
then streptavidin-biotin-horseradish peroxidase complex
at 37°C for 1 h. A negative control was included with each
run by substituting the primary antibody with non-
immune rabbit serum. Cellular nuclei were counter-
stained with ameliorative Gill's hematoxylin. Representa-
tive images were taken under a light microscope (×400) in
randomly-selected fields.
Statistical analysis
Statistical analysis of the differences in tumor volume,
percent apoptosis and microvessel density were per-
formed using one-way analysis of variance(ANOVA). A
value of P < 0.05 was considered to be statistically signifi-
cant.
Results
Enhancement of the anti-tumor effect of CDDP in vitro
In order to test the combined effect of Lip-mS with
CDDP in vitro, we treated LLC cells with NS, CDDP (4
μg/mL), Lip-null (DNA at 1 μg/mL), Lip-mS (DNA at 1
μg/mL) or Lip-mS + CDDP. Growth inhibition was ana-
lyzed by measuring cell viability with flow cytometric
analysis to evaluate the effect of Lip-mS and CDDP on
the induction of apoptosis in LLC cells. Lip-mS + CDDP
treatment significantly increased the proportion (62.6%)
of sub-G1 cells (apoptotic cells) compared with the other
treatments (NS, 8.7%; CDDP, 8.3%; Lip-null,9.0%;Lip-mS,
44.6%) (Fig. 1). Moreover, the interactive in vitro anti-
tumor effect of the combined treatment was greater than
the expected additive effect. The expected combined
apoptotic effect was defined as follows: expected com-
bined effect = Lip-mS effect + CDDP effect - Lip-mS
effect × CDDP effect. The Lip-mS and CDDP treatment
can induce apoptosis 44.6% and 8.3% respectively, so the
expected induction of apoptosis in the combined treat-
ment should be 49.2%. However, the actual induction of
apoptosis in the combined treatment is 62.6%, suggesting
greater than additive treatment effect.
Enhancement of the anti-tumor effects of CDDP in vivo
The anti-tumor effect of Lip-mS in combination with
CDDP was assessed in mice bearing LLC tumors. The
tumor growth curves demonstrated that, relative to NS or
CDDP alone, Lip-mS resulted in effective suppression of
tumor growth, while the combined treatment had a supe-
Figure 1 Induction of apoptosis in LLC cells by treatment with 
Lip-mS and CDDP. LLC cells were treated with NS (a), CDDP (b), Lip-
null(c), Lip-mS (d), or Lip-mS+CDDP (e). Flow cytometric analysis re-
vealed the proportion of sub-G1 cells (apoptotic cells) to be 8.7% (a), 
8.3% (b), 9.0%(c)44.6% (d), and 62.6% (e), respectively.Yu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:46
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rior anti-tumor effect when compared with NS, Lip-mS
or CDDP alone (P < 0.05) (Fig. 2). Moreover, the interac-
tive anti-tumor effects of the combined treatment were
also greater than their expected additive effects. On day
16 after the initiation of Lip-mS administration, the
tumor inhibitory rate (TIR) of the CDDP group was zero.
the TIR of Lip-mS alone was 71.1% and the combination
treatment group was 85.9%. This suggests that combina-
tion treatment increased the inhibition, especially relative
to CDDP (P < 0.05). In order to test by which possible
mechanisms Lip-mS enhanced the anti-tumor effect of
CDDP in vivo. The expression of caspase-9 in different
treatment groups were detected by western blot. And
tumor sections of each group were stained with TUNEL
reagent and anti-CD31 antibody to evaluate the apoptotic
rate and microvessel density. The details were described
in Methods. Caspase-9 was found to be expressed to a
higher extent in Lip-mS + CDDP treatment groups as
compared to other groups(Fig. 3). And an apparent
increase in the number of apoptotic cells was observed
within the tumors treated with the combination of Lip-
mS and CDDP compared with other treatments (P < 0.05)
(Fig. 4). Tumors of the NS and CDDP-treated groups
exhibited high microvessel density, while the density was
reduced in the Lip-mS-alone and combination treatment
groups (Fig. 5). These data suggest that Lip-mS can cause
increased apoptosis of tumor cells and inhibition of
tumor angiogenesis, which may play important roles in
enhancement of the anti-tumor effects of chemotherapy
in vivo.
Discussion
Survivin has received much greater attention in recent
years, thanks not only to its anti-apoptotic effects, but
also its relation to chemoresistance. It was reported that
survivin acts constitutively in a panel of tumor cells, and
approaches designed to inhibit survivin expression or
function may lead to tumor sensitization to chemical and
physical agents [13]. Hence, the combination of genetic
and chemotherapeutic approaches has been a topic of
great interest.
CDDP is widely used for the treatment of a variety of
human tumors such as lung cancer[14]. CDDP is a well-
known DNA damaging agent, and it is currently thought
that DNA platination is an essential first step in its cyto-
toxic activity[15]. However, continuous infusion or multi-
ple administration of CDDP is an excellent regimen for
cancer patients because of its adverse effects [16,17].
Therefore, approaches to improve the sensitivity to drug
doses are a subject of intensive study in cancer care.
Treatments combining genetic and chemotherapeutic
approaches are a relatively new instrument in the fight
against cancer.
Our study combining a Lip-mS genetic approach with
CDDP significantly increased the anti-tumor effects of
single chemotherapy. Moreover, the interactive anti-
tumor effect of the combined treatment was greater than
the expected additive effect. These data suggest that inhi-
bition of survivin using a dominant-negative mutant, sur-
vivin T34A, can sensitize LLC cells to CDDP.
Reduction of apoptosis plays a very important role in
tumor initiation, progression, and drug resistance. The
major apoptosis-signaling pathways are the mitochon-
Figure 2 Lip-mS enhanced the antitumor effects of CDDP in vivo. 
Mice bearing LLC tumors were treated with NS, CDDP, Lip-mS or Lip-
mS +CDDP. Combination treatment reduced the mean tumor volume 
on day 16 when compared with the Lip-mS or CDDP treatment group 
(P < 0.05).
Figure 3 Western blot analysis of caspase-9 expression in differ-
ent groups. Expression of caspase-9 was found in all groups. While no 
significant difference in the expression of anti-actin was found among 
them, caspase-9 was found to be expressed to a higher extent in Lip-
mS + CDDP treatment groups as compared to NS, CDDP alone, Lip-mS 
alone treatment groups.Yu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:46
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drial pathway and the death-receptor pathway. Several
proteins that inhibit apoptosis have been identified,
including the members of the bcl-2 family, such as bcl-2
and bcl-xL, and the IAPs. The anti-apoptotic proteins
bcl-2 and bcl-xL block the apoptotic event of mitochon-
drial cytochrome c release into the cytosol, and have been
shown to mainly inhibit these two above-mentioned
pathways. The gene encoding the IAP survivin has been
cloned, and the protein characterized [18]. Survivin is
thought to be expressed in the G2/M phase of the cell
cycle in a cell cycle-regulated manner, and to be associ-
ated with microtubule formation of the mitotic spin-
dle[19,20].
As a member of the IAP family, survivin can block
apoptosis triggered by a variety of apoptotic-stimulating
factors. It can directly bind to and inhibit caspase-3 and
caspase-7, which act at a common downstream part of
the two major apoptotic pathways, and its overexpression
in tumors has been implicated in resistance to a variety of
apoptotic stimuli, including chemotherapy[17,20]. For
this reason, the survivin antisense gene may facilitate
both apoptotic pathways. Although survivin has long
been considered a potential target for cancer therapy
[18,19,21-25], the use of antisense cDNA and oligonucle-
otides to inhibit its expression has only recently been
described [26,27]. Previous studies have shown that
reduction of survivin expression achieved by antisense
strategies results in apoptotic cell death and sensitization
to anticancer drugs in several tumor cell lines [26,27].
These results suggest that survivin expression is likely
important for cell survival or resistance to chemotherapy
in carcinomas.
CDDP acts in the G2/M phase of the cell cycle. Previ-
ous studies have shown that an increase in chemosensi-
tivity is negatively correlated with survivin expression
and positively correlated with rates of apoptosis[28]. The
results of the study by Kojima et al are consistent with
expression of survivin in the G2/M phase[29]. These
observations are consistent with an earlier finding [26]
that interaction between survivin and microtubules of the
mitotic spindle apparatus is necessary to prevent a default
induction of apoptosis at the G2/M phase of the cell
cycle. And it is reported that cisplatin induced caspase-9
activation and apoptosis in cisplatin-sensitive
tumors[30]. Moreover, in a combination therapy experi-
Figure 4 Combination of Lip-mS and CDDP enhanced the induc-
tion of apoptosis in vivo. Tissue sections from tumor-bearing mice 
treated with NS (a), CDDP (b), Lip-mS (c), or Lip-mS + CDDP (d) were 
stained with FITC-DUTP. Percent apoptosis was determined by count-
ing the number of apoptotic cells and dividing by the total number of 
cells in the field (5 high power fields/slide). (A) Representative Field 
from each group. (B) Percent apoptosis in each group. Values were ex-
pressed as means ± SE. An apparent increase in the number of apop-
totic cells was observed within tumors treated with a combination of 
Lip-mS and CDDP compared with the other treatments (P < 0.05).
Figure 5 Inhibition of intra-tumoral angiogenesis assayed by 
CD31 staining of microvessels. Vascularization within tumors was 
detected by an antibody to CD31; representative images were taken 
under a light microscope (×400) in randomly-selected fields. Tumors of 
the NS (a) and CDDP (b) treatment groups demonstrated high mi-
crovessel density, while those of the Lip-mS (c) and Lip-mS + CDDP (d) 
treatment groups showed apparent inhibition of angiogenesis.Yu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:46
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ment with CDDP , evidence was obtained that antisense-
mediated downregulation of survivin can sensitize tumor
cells to chemotherapy in vitro and in vivo [29].
Conclusions
The survivin mutant had originally gained attention
because it widely and specifically promoted apoptosis
and enhanced chemotherapy, and its function and mech-
anism have been studied in various tumor types
[9,11,12,29]. However, there are many aspects of its
mechanisms that are still unclear. Our data suggest that
the use of survivin T34A deserves further investigation as
a useful approach to lung cancer therapy and in chemo-
therapy with CDDP. It was shown to down-regulate sur-
vivin expression and activity, to cause apoptosis in LLC
cells, and to inhibit tumor growth. In addition, survivin
T34A greatly enhances sensitivity to CDDP. These find-
ings indicate the potential of this combination of a domi-
nant-negative mutant--survivin T34A and administration
of CDDP, or other chemotherapy, as a new therapeutic
strategy for lung cancer.
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